Johnson & Johnson Ratings Put On CreditWatch Negative by S&P Global

MT Newswires Live

2025/01/15

Johnson & Johnson's (JNJ) shares were edging lower Tuesday after S&P Global Ratings said it placed nearly all of the company's ratings on creditwatch with negative implications following the drugmaker's $14.6 billion deal to acquire Intra-Cellular Therapies (ITCI).

The ratings agency said that the negative creditwatch reflects concerns that while the company has reduced its debt after each acquisition, its leverage may occasionally exceed 1.0 times, which the ratings agency views as inconsistent with the current 'AAA' rating.

S&P said it plans to resolve the creditwatch status after reviewing the company's full-year 2024 results, 2025 guidance, as well as more details about the transaction, and additional information on management's financial policies regarding future mergers and acquisitions. It also said it will assess the impact of the ongoing talcum powder litigation settlement on the company's adjusted leverage.

Price: 143.64, Change: -0.83, Percent Change: -0.57

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2503500127"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503500127\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503500127?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 02:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503500127","market":"fut","top_or_hot":-1,"title":"Johnson & Johnson Ratings Put On CreditWatch Negative by S&P Global","media":"MT Newswires Live","content":"<html><body><p> Johnson &amp; Johnson's (JNJ) shares were edging lower Tuesday after S&amp;P Global Ratings said it placed nearly all of the company's ratings on creditwatch with negative implications following the drugmaker's $14.6 billion deal to acquire Intra-Cellular Therapies (ITCI).</p><p>The ratings agency said that the negative creditwatch reflects concerns that while the company has reduced its debt after each acquisition, its leverage may occasionally exceed 1.0 times, which the ratings agency views as inconsistent with the current 'AAA' rating.</p><p>S&amp;P said it plans to resolve the creditwatch status after reviewing the company's full-year 2024 results, 2025 guidance, as well as more details about the transaction, and additional information on management's financial policies regarding future mergers and acquisitions. It also said it will assess the impact of the ongoing talcum powder litigation settlement on the company's adjusted leverage.</p><p>Price: 143.64, Change: -0.83, Percent Change: -0.57</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson Ratings Put On CreditWatch Negative by S&P Global</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson Ratings Put On CreditWatch Negative by S&P Global\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-01-15 02:51</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Johnson &amp; Johnson's (JNJ) shares were edging lower Tuesday after S&amp;P Global Ratings said it placed nearly all of the company's ratings on creditwatch with negative implications following the drugmaker's $14.6 billion deal to acquire Intra-Cellular Therapies (ITCI).</p><p>The ratings agency said that the negative creditwatch reflects concerns that while the company has reduced its debt after each acquisition, its leverage may occasionally exceed 1.0 times, which the ratings agency views as inconsistent with the current 'AAA' rating.</p><p>S&amp;P said it plans to resolve the creditwatch status after reviewing the company's full-year 2024 results, 2025 guidance, as well as more details about the transaction, and additional information on management's financial policies regarding future mergers and acquisitions. It also said it will assess the impact of the ongoing talcum powder litigation settlement on the company's adjusted leverage.</p><p>Price: 143.64, Change: -0.83, Percent Change: -0.57</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ITCI","symbol_name":"Intra-Cellular Therapies Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503500127","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503500127","pubTimestamp":1736880705,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Johnson & Johnson's  shares were edging lower Tuesday after S&P Global Ratings said it placed nearly all of the company's ratings on creditwatch with negative implications following the drugmaker's $14.6 billion deal to acquire Intra-Cellular Therapies .The ratings agency said that the negative creditwatch reflects concerns that while the company has reduced its debt after each acquisition, its leverage may occasionally exceed 1.0 times, which the ratings agency views as inconsistent with the current 'AAA' rating.S&P said it plans to resolve the creditwatch status after reviewing the company's full-year 2024 results, 2025 guidance, as well as more details about the transaction, and additional information on management's financial policies regarding future mergers and acquisitions. It also said it will assess the impact of the ongoing talcum powder litigation settlement on the company's adjusted leverage.Price: 143.64, Change: -0.83, Percent Change: -0.57","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"ITCI":"Intra-Cellular Therapies Inc.","JNJ":"强生","SPGI":"标普全球"},"translate_title":"标准普尔全球将强生评级列入信用观察负面","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ITCI":0.9,"SPGI":1,"JNJ":1},"content_text":"Johnson & Johnson's (JNJ) shares were edging lower Tuesday after S&P Global Ratings said it placed nearly all of the company's ratings on creditwatch with negative implications following the drugmaker's $14.6 billion deal to acquire Intra-Cellular Therapies (ITCI).The ratings agency said that the negative creditwatch reflects concerns that while the company has reduced its debt after each acquisition, its leverage may occasionally exceed 1.0 times, which the ratings agency views as inconsistent with the current 'AAA' rating.S&P said it plans to resolve the creditwatch status after reviewing the company's full-year 2024 results, 2025 guidance, as well as more details about the transaction, and additional information on management's financial policies regarding future mergers and acquisitions. It also said it will assess the impact of the ongoing talcum powder litigation settlement on the company's adjusted leverage.Price: 143.64, Change: -0.83, Percent Change: -0.57","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}